Processing...
Clinical Trials for Melanoma
Search
Search
There are 158 active trials for advanced/metastatic melanoma.
Click on a trial to see more information.
158 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with select advanced/metastatic solid tumors after standard therapy (melanoma, cSCC, Merkel cell, NSCLC, HNSCC, gastric/GEJ, RCC, HGSOC, TNBC) receive AZD6750, an investigational CD8-guided IL-2 designed to preferentially activate CD8+ T cells; a separate module enrolls NSCLC (including 1L PD-L1 ≥1%) to receive AZD6750 plus rilvegostomig, a bispecific PD-1/TIGIT antibody. Key exclusions include uncontrolled CNS disease, active autoimmune disease, prior severe I/O toxicities, and in the NSCLC module prior anti-TIGIT or targetable driver-positive 1L disease.
ClinicalTrials.gov ID: NCT07115043
TrialFetch AI summary: Adults with unresectable stage III/IV melanoma that has progressed after at least one prior systemic regimen and shows MC1R positivity on 68Ga‑VMT02 PET or 203Pb‑VMT01 SPECT receive [212Pb]VMT01, an MC1R-targeted peptide alpha-emitting radiopharmaceutical, as monotherapy or combined with nivolumab. Up to three [212Pb]VMT01 cycles are given about 8 weeks apart, with nivolumab dosed Q4W in combo cohorts; patients need ECOG 0–1 and adequate organ function, and key exclusions apply for prior radiopharmaceuticals and immune-related contraindications.
ClinicalTrials.gov ID: NCT05655312
TrialFetch AI summary: Adults with HLA‑A*02:01–positive unresectable or metastatic cutaneous melanoma (post–PD‑1) or synovial sarcoma needing further therapy receive autologous PRAME‑targeted TCR‑T cells (ACTengine IMA203) after lymphodepletion plus low‑dose IL‑2, combined with a PRAME mRNA vaccine (mRNA‑4203) to boost PRAME‑specific T‑cell responses. Key exclusions include active brain metastases, significant autoimmune/cardiac disease, prior allogeneic transplant, active viral infections, and hypersensitivity to study agents.
ClinicalTrials.gov ID: NCT06946225
TrialFetch AI summary: For adults with ECOG 0–1 and measurable unresectable/metastatic disease, this study enrolls either ER+/HER2− breast cancer with actionable PIK3CA/AKT1/PTEN alterations after progression on ≥2 endocrine-based regimens (candidate for fulvestrant + capivasertib) or cutaneous melanoma progressing after prior immune checkpoint inhibitor therapy (and after/intolerant to BRAF/MEK inhibitors if BRAF V600–mutant). Patients receive dual polyamine blockade with oral AMXT 1501 (polyamine transport inhibitor) plus oral DFMO/eflornithine (irreversible ornithine decarboxylase inhibitor) added to standard therapy—fulvestrant + capivasertib in breast cancer or pembrolizumab in melanoma.
ClinicalTrials.gov ID: NCT07287917
TrialFetch AI summary: This trial enrolls adult patients with advanced solid tumors, including NSCLC, who have progressed after anti-PD-1/PD-L1 therapy to evaluate MEM-288, an oncolytic adenovirus with immunostimulatory properties, alone and in combination with the PD-1 inhibitor nivolumab.
ClinicalTrials.gov ID: NCT05076760
TrialFetch AI summary: This trial targets adult patients with advanced solid malignancies and evaluates the safety and efficacy of CRX100, an investigational immunotherapy combining autologous T cells and oncolytic vaccinia virus, as monotherapy and in combination with Pembrolizumab.
ClinicalTrials.gov ID: NCT04282044
TrialFetch AI summary: The trial involves adult patients with advanced solid tumors harboring specific RAS mutations, including KRAS G12, who have progressed after standard therapies, evaluating the safety and tolerability of RMC-6236, an oral selective inhibitor targeting active RAS(ON) with a novel 'tri-complex' mechanism. This investigational drug shows promising early efficacy, especially in KRAS G12X-related pancreatic and non-small cell lung cancers.
ClinicalTrials.gov ID: NCT05379985
TrialFetch AI summary: This trial involves adult patients with advanced or metastatic solid tumors and evaluates the safety and therapeutic activity of GI-101, a bispecific fusion protein targeting CTLA-4 and the IL-2 pathway, as a single agent and in combination with pembrolizumab, lenvatinib, or radiotherapy.
ClinicalTrials.gov ID: NCT04977453
TrialFetch AI summary: This trial enrolls adults with advanced solid tumors—including specific expansion cohorts for RCC, NSCLC, and PD-L1-negative NSCLC—who have progressed after or cannot tolerate standard therapies or are treatment naïve for metastatic disease without actionable mutations. Patients receive STK-012, an engineered IL-2 partial agonist that selectively stimulates CD25+ T cells with reduced toxicity risk, as monotherapy or in combination with pembrolizumab, and in NSCLC, with pembrolizumab plus pemetrexed and carboplatin.
ClinicalTrials.gov ID: NCT05098132
TrialFetch AI summary: Adult patients with unresectable locally advanced or metastatic solid tumors (including melanoma, renal cell carcinoma, or PD-L1-positive NSCLC) who have progressed after or are ineligible for standard therapies receive AU-007, a novel monoclonal antibody that redirects IL-2 activity toward effector T and NK cells by blocking IL-2Rα, as monotherapy or in combination with recombinant IL-2 and/or checkpoint inhibitors. Patients must have adequate organ function, resolved prior immunotherapy toxicity, and measurable or evaluable disease.
ClinicalTrials.gov ID: NCT05267626